|

Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG

RECRUITINGSponsored by Eko Devices, Inc.
Actively Recruiting
SponsorEko Devices, Inc.
Started2025-06-15
Est. completion2026-08-31
Eligibility
Age18 Years+
Locations3 sites

Summary

This is a prospective, observational study evaluating whether heart sounds (phonocardiograms) and three-lead electrocardiograms (ECGs) recorded using the Eko CORE 500 digital stethoscope can help detect pulmonary hypertension (PH) and low left ventricular ejection fraction (EF ≤ 40%). PH is a condition characterized by high blood pressure in the pulmonary arteries, which can lead to heart failure and carries significant risks if undiagnosed. Low EF, which indicates reduced pumping ability of the heart, is also associated with increased risk of severe cardiac events but can remain undetected because patients often have no symptoms or only nonspecific symptoms. In this study, adults undergoing clinically indicated echocardiograms at outpatient sites will be invited to participate. Participants will complete a single study session lasting about 20 minutes, during which heart sounds and a three-lead ECG will be collected using the Eko CORE 500 device. If participants have had a clinical 12-lead ECG within 30 days of their echocardiogram, those data may also be used for analysis. The echocardiogram performed as part of routine care within seven days before or after the Eko CORE 500 recording will serve as the reference standard to confirm the presence or absence of PH and low EF. Up to 3,850 participants may be enrolled across multiple sites to ensure that approximately 3,500 complete the study. The data collected will be used to develop and validate artificial intelligence (AI) algorithms that aim to detect PH and identify low EF, potentially enabling earlier and simpler screening for these conditions in clinical practice.

Eligibility

Age: 18 Years+
Inclusion Criteria:

* Adults aged 18 years and older
* Able and willing to provide informed consent
* Completed a clinical echocardiogram within 7 days before or after study procedures

Exclusion Criteria:

* Unwilling or unable to provide informed consent
* Patients who are hospitalized
* Patients undergoing echocardiography with a limited echocardiogram

Conditions3

Heart DiseaseHeart Failure With Reduced Ejection FractionHypertension, Pulmonary

Locations3 sites

Prairie Cardiovascular
O'Fallon, Illinois, 62269
Lauren McNeil217.492.9115lmcneil@prairieresearch.com
Prairie Education & Research Cooperative
Springfield, Illinois, 62769
Lauren McNeil217.492.9115lmcneil@prairieresearch.com
St Johns Hospital, Springfield
Springfield, Illinois, 62769
Lauren McNeil217.492.9115lmcneil@prairieresearch.com

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.